Mirum Pharmaceuticals (MIRM) Stock Statistics & Valuation Metrics

Mirum Pharmaceuticals has a market cap or net worth of MXN 103.72B. The enterprise value is MXN 7.74B.

Market Cap

MXN 103.72B

Enterprise Value

MXN 7.74B

Mirum Pharmaceuticals has 64,932,205 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

64,932,205

Owned by Insiders

7.53%

Owned by Institutions

49.19%

Mirum Pharmaceuticals’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -3.46%.

Return on Equity (ROE)

-0.07

Return on Assets (ROA)

-0.03

Return on Invested Capital (ROIC)

-3.46%

Return on Capital Employed (ROCE)

-0.03

Revenue Per Employee

1.20M

Profits Per Employee

-53.96K

Employee Count

433

Asset Turnover

0.62

Inventory Turnover

4.04

The current PE Ratio of Mirum Pharmaceuticals is -5.84. Mirum Pharmaceuticals’s PEG ratio is 0.00.

PE Ratio

-5.84

PS Ratio

8.93

PB Ratio

-516.87

Price to FCF

-12.05

Price to Operating Cash Flow

-11.81

PEG Ratio

0.00

In the last 12 months, Mirum Pharmaceuticals had revenue of 521.31M and earned -23.36M in profits. Earnings per share was -0.47.

Revenue

521.31M

Gross Profit

420.73M

Operating Income

-22.14M

Pretax Income

-21.43M

Net Income

-23.36M

EBITDA

17.21M

Earnings Per Share (EPS)

-0.47

In the last 12 months, operating cash flow was -456.03M and capital expenditures -2.14M, giving a free cash flow of -458.17M billion.

Operating Cash Flow

-456.03M

Free Cash Flow

-458.17M

Free Cash Flow per Share

-7.23

Mirum Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-8.30%

Earnings Yield

-15.97%

Beta

0.19

52-Week Price Change

17.98%

50-Day Moving Average

1301.30

200-Day Moving Average

1267.41

Relative Strength Index (RSI)

―

Average Volume (3m)

―

Mirum Pharmaceuticals upcoming earnings date is Nov 03, 2026, After Close (Not Confirmed).

Last Earnings Date

Aug 05, 2026

Next Earnings Date

Nov 03, 2026

Ex-Dividend Date

―

Mirum Pharmaceuticals as a current ratio of 2.67, with Debt / Equity ratio of 101.51%

Current Ratio

2.67

Quick Ratio

2.55

Debt to Market Cap

0.08

Net Debt to EBITDA

1.32

Interest Coverage Ratio

-1.54

In the past 12 months, Mirum Pharmaceuticals has paid 1.94M in taxes.

Income Tax

1.94M

Effective Tax Rate

-0.09

Mirum Pharmaceuticals EV to EBITDA ratio is -7.66, with an EV/FCF ratio of -12.98.

EV to Sales

9.63

EV to EBITDA

-7.66

EV to Free Cash Flow

-12.98

EV to Operating Cash Flow

-13.05

Mirum Pharmaceuticals has MXN 438.29M in cash and marketable securities with MXN 760.54M in debt, giving a net cash position of -MXN 322.25M billion.

Cash & Marketable Securities

MXN 438.29M

Total Debt

MXN 760.54M

Net Cash

-MXN 322.25M

Net Cash Per Share

-MXN 4.96

Tangible Book Value Per Share

-MXN 4.07

Gross margin is 81.70%, with operating margin of -17.42%, and net profit margin of -139.18%.

Gross Margin

81.70%

Operating Margin

-17.42%

Pretax Margin

-138.75%

Net Profit Margin

-139.18%

EBITDA Margin

-125.68%

EBIT Margin

-129.88%

The average price target for Mirum Pharmaceuticals is MXN 2,865.84, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

MXN 2,865.84

Price Target Upside

93.37% Upside

Analyst Consensus

Strong Buy

Analyst Count

12

Revenue Growth Forecast

30.61%

EPS Growth Forecast

-962.82%

Smart Score

6

AI Score

―